Table of Contents
<< Previous Issue | Feb 2018 (Vol: 2018, Issue: 2) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Idera and BioCryst Merge to Form Rare Disease Company
-
Seattle Genetics Strengthens Pipeline with Acquisition of Cascadian for US$614 M
-
Sanofi Makes Second Big Buy of the Month with Ablynx Acquisition
-
Roche Acquires Oncology Data Specialist Flatiron in US$1.9 B Deal
- Section: Research & Development
-
J&J Locks Theravance’s Phase I Inflammatory Bowel Disease Asset for US$1 B
-
BMS Inks US$3.63 B Immuno-Oncology Collaboration with Nektar Therapeutics